Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 6th February 2025
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD responds to Solensia injection concerns
Solensia is used to alleviate osteoarthritis pain in cats.
Anaphylaxis has been added to the SPC as an adverse event.

The VMD has added anaphylaxis to the SPC of Solensia 7 mg/ml Solution for Injection for Cats.

It says that this is a rare side effect, with such adverse events affecting fewer than three animals for every 1000 doses of Solensia sold.

Solensia is used to alleviate osteoarthritis pain in cats. It contains the active ingredient frunevetmab.

Anaphylaxis joins effects such as alopecia, dermatitis, pruritus on the list of adverse effects.

The VMD says that is constantly reviewing adverse event data for all medicines.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.